Michael Grissinger - Jan 1, 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Rachelle Jacques, as Attorney-in-Fact for Michael Grissinger
Stock symbol
AKTX
Transactions as of
Jan 1, 2024
Transactions value $
$0
Form type
3
Date filed
1/2/2024, 06:41 PM
Previous filing
Aug 24, 2023
Next filing
Jun 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKTX Ordinary Shares, par value $0.0001 per share 20M Jan 1, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 1.3M $0.03 Direct F1
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 1.3M $0.02 Direct
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 1.3M $0.02 Direct
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 1.3M $0.02 Direct
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 1.3M $0.02 Direct
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 1.3M $0.01 Direct
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 3.7M $0.00 Direct
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 5M $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The stock option vested and became exercisable in four equal installments of twenty-five percent (25%), with the with the first installment vesting on January 23, 2019 and an additional 25% vesting on each annual anniversary of the vesting date thereafter.
F2 Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2024 Annual General Meeting.

Remarks:

See Exhibit 24.1 - Power of Attorney